UA Frame EN

Welcome to licensed pharmacies in Poland:

Non-prescription medicines delivery across Europe.

Frequently ordered: potency boosters (sildenafil OTC), quit smoking aids.

Bogusław (Anonymous, 80.48.68.) Warszawa 3 years ago

What should I do if the European Food Safety Authority considers titanium dioxide E171 to be carcinogenic and this ingredient is found in the Xyzal tablets I take?

Hello! I use the antihistamine Xyzal for urticaria. In Xyzal on the leaflet it is written that it contains E171 titanium dioxide. A month ago I learned that the EU had recognized E171 titanium dioxide as a harmful cancer. In connection with this my question whether I should continue to calmly accept Xyzal or look for its replacement? What should I do? Thank you for your help.

1 answer, 1 subscriber

* required field

You can drag the photo file here.

* required field

Notify of a new answer.
Other messages will not be sent.

Suggested Products

Space for your product

Your product would fit here?

Set up a sponsored products campaign yourself:

Check

Angelika Talar-Śpionek Pharmacist, Editor

3 years ago

It is true that the European Food Safety Authority (EFSA) has issued a recommendation that the ingredient E171 should not be consumed because it is no longer considered a safe food additive. However, an official ban on the use of E171 has still not been issued, which is why products containing it are still available on the market. Since the substitutes for this drug in tablet form also contain titanium dioxide, you may want to consider changing the tablets to Xyzal syrup: https://www.gdziepolek.pl/produkty/84749/xyzal-plyn/apteki Since this drug is only available on prescription, please consult your doctor, present your concerns and ask for a prescription for syrup.

Appreciate the answerer and highlight the question on the home page
User questions and answers that provide feedback about products are not verified for the purchase or use of the product. Companies often order anonymous comments to form positive opinions about their products, or negative ones about competitors. Therefore, be guided by the information in the pharmacists' responses in the first place.

Specialists